Barriers to use of pharmacotherapy for addiction disorders and how to overcome them

Current Psychiatry Reports

Volumn 13, Issue 5, 2011, Pages 374-381

  Oliva, Elizabeth M ^a   Maisel, Natalya C ^a   Gordon, Adam J ^b,c   Harris, Alex H S ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Alcohol; Barriers; Facilitators; Medication assisted treatment; Opioids; Pharmacologic interventions; Pharmacotherapy; Substance abuse treatment; Substance dependence

Indexed keywords

ACAMPROSATE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DISULFIRAM; METHADONE; NALTREXONE; PLACEBO;

ALCOHOLISM; DRUG COST; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; EDUCATION PROGRAM; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH PERSONNEL ATTITUDE; HEALTH PROGRAM; HUMAN; INFORMATION DISSEMINATION; INTEGRATED HEALTH CARE SYSTEM; MEDICAL EDUCATION; MEDICAL INFORMATION; OPIATE ADDICTION; PATIENT CARE; PROFESSIONAL KNOWLEDGE; PSYCHOPHARMACOTHERAPY; REVIEW;

ALCOHOL DETERRENTS; ALCOHOLISM; ANALGESICS, OPIOID; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE;

EID: 80755175247     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-011-0222-2     Document Type: Review

References (76)

1. Office of Applied Studies: Results from the 2009 National Survey on Drug Use and Health: Detailed Tables. 2009, Substance Abuse and Mental Health Services Administration: Rockville, MD.
2. Office of National Drug Control Policy: The Economic Costs of Drug Abuse in the United States, 1992-2002. 2004, Executive Office of the President: Washington, DC.
3. Rehm J, Mathers C, Popova S, et al. Alcohol and global health 1: Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223-33.
4. Harris AHS, Kivlahan DR, Bowe T, et al. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61(4):392-8.
5. Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21-7.
6. Mark TL, Kranzler HR, Poole VH, et al. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1-3):345-9.
7. Substance Abuse and Mental Health Services Administration: The N-SSATS Report: Services Provided by Substance Abuse Treatment Facilities in the United States. Office of Applied Studies 2009: Rockville, MD.
8. • Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36:584-9. This article describes data obtained from recent US national surveys regarding pharmacotherapy for substance use disorders and discusses facilitators and barriers to pharmacotherapy adoption.
9. ® (PCPI), and the National Committee for Quality Assurance: Substance Use Disorders: Physician Performance Measurement Set 2008. Available at http://www.ama-assn.org/ama1/pub/upload/mm/370/sud-ws-final.pdf Accessed May 2010.
10. Department of Veterans Affairs and Department of Defense: Management of Substance Use Disorders (SUD). Office of Quality and Performance, VA and Quality Management Office, United States Army MEDCOM 2009: Washington, DC.
11. Soyka M, Kranzler HR, Berglund M, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry. 2008;9(1):6-23. (Pubitemid 351250516)
12. Soyka M, Kranzler HR, van den Brink W, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 2: opioid dependence. World J Biol Psychiatry. 2011;12:160-87.
13. Boothby LA, Doering PL. Acamprosate for the treatment of alcohol dependence. Clin Ther. 2005;27(6):695-714. (Pubitemid 41583518)
14. Snyder JL, Bowers TG. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse. 2008;34(4):449-61. (Pubitemid 351913745)
15. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36(6):544-52. (Pubitemid 33085631)
16. Bouza C, Angeles M, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811-28. (Pubitemid 38869838)
17. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 2010;16(19):2091-7.
18. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010, Issue 12. Art. No.: CD001867.
19. Kranzler HR, Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta analysis. Alcohol Clin Exp Res. 2001;25(9):1335-41. (Pubitemid 32868343)
20. Rösner S, Leucht S, Lehert P, et al. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11-23.
21. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, Issue 9. Art. No.: CD004332.
22. Mattick R, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009, Issue 3. Art. No.: CD002209.
23. Mattick R, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008, Issue 2. Art. No.: CD002207.
24. Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double blind trial with 405 opioid dependent patients. Addiction. 2003;98(4):441-52. (Pubitemid 36458126)
25. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104(6):982-92.
26. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96(9):1267-78. (Pubitemid 32835704)
27. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007, 11(9):iii-171.
28. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry. 2001;158(8):1200-4. (Pubitemid 32717691)
29. Sullivan LE, Fiellin DA. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med. 2008;148(9):662-70. (Pubitemid 351669111)
30. Becker WC, Fiellin DA, Merrill JO, et al. Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend. 2008;94(1-3):207-13.
31. Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008;3(1):17.
32. Finkelstein R, Netherland J, Sylla L, et al. Policy implications of integrating buprenorphine/naloxone treatment and HIV care. J Acquir Immune Defic Syndr. 2011;56:S98-S104.
33. Knudsen HK, Roman PM, Oser CB. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. J Addict Med. 2010;4(2):99-107.
34. Lobmaier P, Gossop M, Waal H, et al. The pharmacological treatment of opioid addiction-a clinical perspective. Eur J Clin Pharmacol. 2010;66(6):537-45.
35. Mark TL, Kassed CA, Vandivort-Warren R, et al. Barriers to the use of medications to treat alcoholism. Am J Addict. 2003;12(4):281-94. (Pubitemid 37175521)
36. Rieckmann T, Kovas AE, Rutkowski BA. Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities. J Psychoactive Drugs. 2010; SUPPL.ement 6:227-38.
37. Thomas CP, Wallack SS, Lee S, et al. Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat. 2003;24(1):1-11. (Pubitemid 36315767)
38. • Weber EM. Failure of physicians to prescribe pharmacotherapies for addiction: regulatory restrictions and physician resistance. J Health Care Law Policy 2010;13:49-76. This article provides a good historical overview of factors contributing to low utilization of pharmacotherapies for addiction.
39. Horgan CM, Reif S, Hodgkin D, et al. Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008;34(2):147-56. (Pubitemid 351163511)
40. Knudsen HK, Abraham AJ, Johnson JA, et al. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2009;37(3):307-12.
41. Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2007;87(2-3):164-74. (Pubitemid 46215923)
42. Stöver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011;17(1):44-54.
43. Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393-8.
44. Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244-51.
45. Heinrich CJ, Hill CJ. Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res. 2008;43(3):951-70. (Pubitemid 351623961)
46. Albright J, Ciaverelli R, Essex A, et al. Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. J Addict Med. 2010;4(4):197-203.
47. Humphreys K, Trafton JA, Oliva EM. Does following researchderived practice guidelines improve opiate-dependent patients' outcomes under everyday practice conditions?: results of the multisite opiate substitution treatment study. J Subst Abuse Treat. 2008;34(2):173-9. (Pubitemid 351187800)
48. Abraham AJ, Ducharme LJ, Roman PM. Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs. 2009;70(4):628-35.
49. Bacha J, Reast S, Pearlstone A. Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addict Relat Clin Probl. 2010;12(3):9-19.
50. Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24(2):218-25.
51. Drake R, Skinner J, Goldman HH. What explains the diffusion of treatments for mental illness? Am J Psychiatry. 2008;165(11):1385-92.
52. Wallack SS, Thomas CP, Martin TC, et al. Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a Congressionally approved medication. J Behav Health Serv Res. 2010;37(1):64-78.
53. Gordon A, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215-24.
54. Fitzgerald J, McCarty D. Understanding attitudes toward use of medication in substance abuse treatment: a multilevel approach. Psychol Serv. 2009;6(1):74-84.
55. Lundgren L, Krull I, Zerden LS, et al. Community based addiction treatment staff attitudes about the usefulness of evidence-based addiction treatment and CBO organizational linkages to research institutions. Eval Program Plann. 2011;34(4):356-65.
56. Dackis C, O'Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci. 2005;8(11):1431-6. (Pubitemid 41573650)
57. Littleton JM, de Witte P, Litten R, et al. Challenges to medications development in treating alcohol dependence: an international perspective. Alcohol Alcohol. 2004;39(4):271-5. (Pubitemid 38968079)
58. Center for Substance Abuse Treatment: Incorporating Alcohol Pharmacotherapies Into Medical Practice. Treatment Improvement Protocol (TIP) Series 49. Substance Abuse and Mental Health Services Administration 2009: Rockville, MD.
59. McAuley K, Maurice D, Ferguson A, et al. Evaluation of the impact of medication assisted treatment in Maine. Department of Health and Human Services, Maine Office of Substance Abuse. South Portland: Hornby Zeller Associates, Inc.; 2010.
60. McCarty D, Perrin NA, Green CA, et al. Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. Drug Alcohol Depend. 2010;111(3):235-40.
61. Fornili K, Burda C. Buprenorphine prescribing: why physicians aren't and nurse prescribers can't. J Addict Nurs. 2009;20(4):218-26.
62. Cunningham CO, Sohler NL, McCoy K, et al. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336-40. (Pubitemid 43723598)
63. Thomas SE, Miller PM. Knowledge and attitudes about pharmacotherapy for alcoholism: a survey of counselors and administrators in community-based addiction treatment centres. Alcohol Alcohol. 2007;42(2):113-8. (Pubitemid 47072102)
64. O'Connor PG, Nyquist JG, McLellan AT. Integrating addiction medicine into graduate medical education in primary care: the time has come. Ann Intern Med. 2011;154(1):56-9.
65. Martino S, Brigham GS, Higgins C, et al. Partnerships and pathways of dissemination: The National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network. J Subst Abuse Treat. 2010;38(SUPPL.ement 1):S31-43.
66. Gordon AJ, Liberto J, Granda S, et al. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008;17(6):459-62.
67. Gordon AJ, Liberto J, Granda S, et al. Physician training is never a failure. Am J Addict. 2009;18(4):337-8.
68. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-17. (Pubitemid 44794003)
69. West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13(S1):S8-S16. (Pubitemid 38585687)
70. Ridge G, Gossop M, Lintzeris N, et al. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abuse Treat. 2009;37(1):95-100.
71. Cunningham CO, Kunins HV, Roose RJ, et al. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325-9. (Pubitemid 47247300)
72. Turner BJ, Laine C, Lin Y, et al. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769-76. (Pubitemid 41138966)
73. Strobbe S, Mathias L, Gibbons PW, et al. Buprenorphine clinic for opioid maintenance therapy: program description, process measures, and patient satisfaction. J Addict Nurs. 2011;22:8-12.
74. Egan JE, Casadonte P, Gartenmann T, et al. The physician clinical support system-buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25(9):936-41.
75. Abraham AJ, Rieckmann T, McNulty T, et al. Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addict Behav. 2011;36(6):576-83.
76. Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician. 2011;57(3):281-9.